Caribou Biosciences has reported data from the ongoing ANTLER Phase I trial of allogeneic anti-CD19 CAR-T cell therapy, CB-010, in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) patients.
The ongoing, open-label, multicentre Phase I clinical trial was designed to evaluate the efficacy and safety of CB-010, the company’s lead allogeneic cell therapy, in r/r B-NHL patients.
Go deeper with GlobalData
It includes two parts; Part A is a three plus three dose escalation phase that will assess CB-010’s safety at multiple dose levels and establish the recommended dose for Phase II.
Part B is a dose expansion phase and will determine the tumour response following a single CB-010 dose as its primary objective.
The new 12-month clinical data from the trial’s first cohort demonstrated long-term durability after a single infusion of CB-010 at the initial dose level one (40×106 CAR-T cells).
Findings showed that all the participants in the cohort achieved a complete response (CR) as best response, three out of six participants maintained a durable CR at six months, and two of them maintained a long-term CR at the 12-month scan.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to CB-010, based on the initial data.
Caribou president and CEO Rachel Haurwitz said: “With next-generation CRISPR genome-editing technology, the promise of allogeneic cell therapies has advanced significantly, and the early results seen in the ANTLER trial to date are a reflection of that potential.
“The long-term durability at dose level one is comparable to autologous cell therapies and we believe CB-010 has the potential to set a new therapeutic bar for what allogeneic anti-CD19 CAR-T cell therapies can achieve.
“We are further encouraged by receiving RMAT and Fast Track designations for CB-010 from the FDA, which is a testament to both the encouraging initial ANTLER data and the need for novel therapies for patients with relapsed or refractory B-NHL.”
The company is currently enrolling participants at dose level three.
Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
